Abbott trims 2026 profit forecast on Exact deal hit, shares fall [Globe and Mail, The (Toronto, Canada)]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Globe and Mail, The
That contribution was evident in first-quarter results, where growth in cancer diagnostics and continued strength in medical device demand helped Abbott post a modest beat on both earnings and revenue. The deal, one of Abbott's largest acquisitions, is a major push into the fast-growing cancer diagnostics market. It gives the company access to Exact's flagship colorectal cancer test Cologuard and early-stage breast cancer test Oncotype DX, helping offset revenue declines from its COVID-19 testing kits. The company said the first-quarter results “aligned with our expectations to start the year.” On an adjusted basis, the company reported profit per share of US$1.15, compared with analysts' estimate of US$1.14, according to data compiled by LSEG. Total revenue was US$11.16-billion, compared with expectations of US$11-billion. Abbott and rival continuous glucose monitor (CGM) makers such as Dexcom and Medtronic are riding a surge in demand as diabetes awareness rises, insurance
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [Yahoo! Finance]Yahoo! Finance
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test [TheStreet.com]TheStreet.com
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestPR Newswire
- Abbott Laboratories (ABT) had its price target lowered by Royal Bank Of Canada from $135.00 to $130.00. They now have an "outperform" rating on the stock.MarketBeat
- Abbott Laboratories (ABT) had its price target lowered by Sanford C. Bernstein from $125.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
ABT
Earnings
- 4/16/26 - Beat
ABT
Sec Filings
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- 4/2/26 - Form 4
- ABT's page on the SEC website